Introduction
The optimal treatment for high-risk soft tissue sarcoma (STS) in adults remains a challenge for the multidisciplinary approach in modern oncology. Patients with large primary or recurrent STS (tumour size >5 cm, histologic grade II or III, deep) remain at increased risk for distant metastases and tumour-related mortality. The tendency for early haematogenous spread as a characteristic feature (especially STS) may explain why distant metastases still occur in high-risk patients despite aggressive local treatment. Also, the invasiveness or the anatomic location of locally advanced tumours often prevent resection with adequate margins, and the toxicity of radiotherapy limits the use of potentially therapeutic doses with a negative impact on local control.
High-risk soft tissue sarcoma and prognostic factors
On the basis of a large database, a postoperative nomogram was developed at the Memorial Sloan Kettering Cancer Center (MSKCC) [1] . The MSKCC nomogram combines various important prognostic factors to predict the probability of sarcoma-specific death providing a useful tool for patient stratification and clinical trial eligibility determination. Recently the variables known to have a prognostic role in adults have shown to be relevant also in the outcome of pediatric patients with adult type STS [2 ] .
With regard to site, about half of STSs are localized in the lower or upper extremities. Purpose of review On the basis of the definition of high-risk soft tissue sarcomas and prognostic factors, the most recent developments of preoperative treatment strategies with special emphasis on regional hyperthermia combined chemotherapy are reviewed.
Recent findings
The most important prognostic factors (e.g. size, grade, depth and resection margins) for localized soft tissue sarcomas have been defined to predict the probability of sarcoma-specific death providing a useful tool for patient stratification and clinical trial eligibility determination that are also relevant in the outcome of paediatric patients with adult type soft tissue sarcomas. Clinical research on innovative preoperative treatment strategies has essentially focused on the combination of preoperative radiochemotherapy or chemotherapy alone, but unfortunately the reported results are based upon retrospective analysis or nonrandomized phase II studies with small sample size. For the use of regional hyperthermia (RHT) therapy, phase II studies have advocated a possible benefit of the use of regional hyperthermia in combination with chemotherapy targeting the heating field to the region of tumour burden. [11, 12] . Although retroperitoneal STSs are more uncommon in children, complete resection and a low histological grade are associated with significantly better disease-specific survival [13 ] . In contrast to STS of extremities, the disease-related mortality rate of retroperitoneal STS is mostly determined by local recurrence [14] .
Innovative preoperative treatment strategies
On the basis of the information given with regard to prognostic factors, it can be concluded that the tendency for metastatic spread depends on high-risk factors (e.g. grade, size and depth of the tumour). The management of high-risk STS should be multidisciplinary and should involve a team approach at specialized centres to optimize the interaction between disciplines and to minimize inappropriate treatment outcome [15 ] . Among the treatment modalities, adequate surgery followed by radiotherapy remains to be of key importance at least for local control. Although small, superficial and low-grade STS tumours may be managed by surgery alone to achieve complete resection, the vast majority of sarcoma patients do not have such tumours. For instance, most of the highgrade localized deep trunk or retroperitoneal sarcomas are presented with large tumour size and invasive growth behaviour and, therefore, surgical resection is often difficult or cannot be achieved with adequate tumour-free margins.
For retroperitoneal STS, local recurrence after primary surgery and high-grade malignancy were associated with the worst survival [16] . A more recent analysis of radiation and surgical treatment has been performed at the M. D. Anderson Cancer Center (MDACC) [17 ] . Overall local control rate was 40% and the 5-year rate for diseasespecific survival was 92% for low-grade compared with 41% for high-grade retroperitoneal STS. The data did not suggest an improved local control with higher doses of external-beam radiation (EBRT) or with the specific use of intraoperative radiotherapy (IORT). In an effort to delineate the role of preoperative radiotherapy in the care of retroperitoneal STS, a prospective, randomized multiinstitutional trial (ACOSOGZ9031) was initiated but the trial was closed secondary to slow accrual.
In parallel, most patients with primary large, and extracompartmental extremity high-risk STS require multimodal treatment strategies to improve the conservative resectability of limb-threatening presentations [18 ] . Current clinical research goals include preoperative concepts in order to control systemic microscopical disease and also to 'down-size' the initial free mass. In general, patients who can be rendered free of gross disease by one or multiple combined treatment modalities have improved prognosis.
A retrospective analysis performed at the MSKCC and the Dana-Farber Cancer Institute (DFCI) compared the results of patients with HR-STS (size >5 cm, high grade and deep) treated with surgery only with those who were given preoperative chemotherapy in addition to local therapy [19] . In the subset of patients with tumours of at least 10 cm in maximum diameter, the 3-year diseasespecific survival was 0.62 [95% confidence interval (CI), 0.53-0.71] for patients treated with surgery alone and 0.83 (95% CI, 0.72-0.95) for patients receiving neoadjuvant chemotherapy. In patients with tumours between 5 and 10 cm in maximum diameter, there was no difference in the outcome.
A more aggressive concept has been tested by the Radiation Therapy Oncology Group (RTOG) for patients with large (>8 cm), high-grade extremity (88%) and body wall (12%) STS using preoperative radiochemotherapy [three cycles of mesna, adriamycin, ifosfamid, and dacarbazine (MAID) with split-course radiation (44 Gy) therapy] followed by resection and postoperative MAID chemotherapy [20] . For 64 evaluable patients, the efficacy results showed 3-year rates for disease-free, distantdisease-free, and overall survival of 56.5, 64.5, and 75.1%, respectively, but three patients (5%) experienced fatal grade 5 toxicities and another 53 patients (83%) grade 4 toxicities. On the basis of these phase II results, the routine use of neoadjuvant chemotherapy combined with radiation outside of a clinical trial was not recommended [21] .
The only randomized trial on neoadjuvant chemotherapy for patients with resectable large (>8 cm) and/or highgrade (GII or GIII) was performed by the European Organization for Research and Treatment of Cancer (EORTC) but has been stopped because of low accrual [22] . However, neoadjuvant treatment showed an objective response rate of 29% but -due to the lack of statistical power -no conclusions regarding the impact of this approach on final outcome in comparison with surgery alone can be drawn.
Regional hyperthermia combined chemotherapy
Within the past 10 years, the application of hyperthermia has been integrated in multimodal treatment strategies against several distinct forms of local advanced malignant tumours and is discussed in an excellent review on the state of the art of hyperthermia [23] . The rationale for the combination of cytotoxic drugs with hyperthermia (increase of temperature in a range of 40-448C) is based on experimental and clinical evidence that heat increases killing of cells by direct thermal toxicity and shows thermal enhancement of drug efficacy. In addition, preclinical results indicate that hyperthermia by inducing the expression of heat-shock proteins might be useful to modulate the immune system. The sarcoma group at the Klinikum Grosshadern Medical Center (KGMC) has focused its interest in the use of regional hyperthermia (RHT) therapy as targeted treatment modality for local advanced high-risk STS to evaluate the efficacy of combined systemic chemotherapy with RHT in such tumours. The first results have been obtained from a phase II study in adult patients mainly with STS [24] . These patients have relapsed after prior surgery and radiation and had not responded to previous standard chemotherapy. As second-line treatment the drug combination of ifosfamid plus etoposide (VP16) was used combined with RHT. The local response rate was 37%. Apart from the unexpected long-term control in a subgroup of patients responding to the combined treatment, the analysis of tumour temperatures (e.g. T20, T50 and T90) achieved by using an electromagnetic deep regional heating device (BSD system, BSD Medical Corporation, Salt Lake City, Utah, USA; Fig. 1 ) according to the European Society of Hyperthermic Oncology (ESHO) quality assurance guidelines [25] showed significantly higher temperature parameters measured in responders than in nonresponders. Two additional consecutive phase II studies have been performed at the KGMC including local advanced primary or recurrent high-risk STS of extremity and nonextremitiy (trunk, abdominal and retroperitoneal tumours), but these patients had not received prior chemotherapy (chemo-naïve patients). In the first study (RHT-91 protocol), 59 patients received four cycles of EIA chemotherapy consisting of etoposide (250 mg/m 2 ), ifosfamide (6 g/m 2 ) and adriamycin (50 mg/m 2 ) combined with RHT. Following this treatment, the patients whose tumours were judged to be resectable underwent surgery. If not preirradiated, the patients also received EBRT followed by four additional cycles of combined chemotherapy and RHT. Treatment related toxicity was acceptable. Median survival was 52 months and the 5-year survival rate was 49% (95% CI 36-96%) -quite impressive for this group of patients with high-risk STS [26] . In the second study (RHT-95 protocol), a similar highrisk STS group (54 patients) received the same treatment as in RHT-91 protocol with the exception that systemic chemotherapy after surgery was given without RHT. The results of this study showed a significant inferior local failure-free survival rate when compared with the results of the RHT-91 protocol but no difference in overall survival [27] . Therefore, comparing the result of both studies, presurgical and postsurgical RHT combined with systemic EIA chemotherapy has shown to be critical to maximize the chance of local control. In addition, a retrospective analysis performed at the KGMC of patients with retroperitoneal and visceral high-risk STS showed that the initial response after four cycles of EIA chemotherapy combined with RHT was predictive for long-term survival [28] . This is the first report on the prognostic importance of initial response to preoperative combined hyperthermic chemotherapy for survival. Most recently, the EORTC and the ESHO completed a multicentric, controlled intergroup phase III clinical trial (EORTC 62961/ESHO RHT-95) in order to define the impact of RHT within the treatment strategy for patients with primary (S1 group) and recurrent (S2 group) or after inadequate surgery (S3 group) high-risk STS (free size 5 cm þ histological grade II or III þ deep þ extracompartmental extension).
In this trial, all patients with high-risk STS -stratified to extremity (E) and to nonextremity (non-E) -received systemic EIA chemotherapy (four cycles etoposide, ifosfamide, adriamycin) and were randomized in two arms (chemotherapy alone vs. chemotherapy and RHT) followed by definitive surgery and radiotherapy. Thereafter, in addition four cycles of the EIA regimen were administered with or without RHT according to the initial randomization (see Fig. 2 ).
The preliminary results have been reported at American Society of Clinical Oncology (ASCO) 2007 [29 ] . After a median follow-up of 24.9 months, an intention-to-treat analysis of 341 randomized patients showed a significantly superior disease-free survival (median 31.7 months vs. 16.2 months, P < 0.01) for patients who received EIA and RHT (n ¼ 169) compared with those treated with EIA chemotherapy alone (n ¼ 172). The objective local response rate and the median local progression-free
Regional hyperthermia in high-risk soft tissue sarcomas Issels 441 survival were also significantly better for the combined treatment arm.
Conclusion
During the last decade, some progress has been made in the use of combined modality treatment strategies.
Owing to the complexity of high-risk STSs, patients should be best treated in referral centres where a dedicated and experienced multidisciplinary team is available. The approach of multimodality treatment using RHT combined systemic chemotherapy within a preoperative and postoperative strategy described in the present study is an innovative treatment option. The technology is safe and effective. Today, RHT can be routinely administered, but only at a few specialized clinical ESHO centres. In the treatment concept for high-risk STS, the potential of RHT to increase the chemotherapeutic effect seems to be proven, but surgery followed by radiotherapy is still the cornerstone for best local free control. The employment of RHT in combination with systemic chemotherapy has been performed and successfully tested in consecutive phase II studies, finally demonstrating a benefit for high-risk STS patients in a large phase III randomized trial, both in terms of local control and disease-free survival. RHT seems to offer an appropriate treatment option for high-risk STS, where local control is difficult to achieve and death may result from inoperable local disease progression.
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